Free Trial

This company has been marked as potentially delisted and may not be actively trading.

RXi Pharmaceuticals (RXII) Competitors

RXi Pharmaceuticals logo

RXII vs. OSTX, EGRX, ELYM, MRNS, HILS, ALLK, CARA, NNVC, IBIO, and ME

Should you be buying RXi Pharmaceuticals stock or one of its competitors? The main competitors of RXi Pharmaceuticals include OS Therapies (OSTX), Eagle Pharmaceuticals (EGRX), Eliem Therapeutics (ELYM), Marinus Pharmaceuticals (MRNS), Hillstream BioPharma (HILS), Allakos (ALLK), Cara Therapeutics (CARA), NanoViricides (NNVC), iBio (IBIO), and 23andMe (ME). These companies are all part of the "medical" sector.

RXi Pharmaceuticals vs. Its Competitors

OS Therapies (NYSE:OSTX) and RXi Pharmaceuticals (NASDAQ:RXII) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

9.6% of RXi Pharmaceuticals shares are owned by institutional investors. 13.8% of OS Therapies shares are owned by insiders. Comparatively, 1.0% of RXi Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

OS Therapies has a net margin of 0.00% compared to RXi Pharmaceuticals' net margin of -4,990.20%. OS Therapies' return on equity of 0.00% beat RXi Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
OS TherapiesN/A N/A -569.57%
RXi Pharmaceuticals -4,990.20%-412.15%-179.54%

OS Therapies has higher earnings, but lower revenue than RXi Pharmaceuticals. OS Therapies is trading at a lower price-to-earnings ratio than RXi Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OS TherapiesN/AN/A-$7.79M-$0.86-1.91
RXi Pharmaceuticals$10K1,073.10-$12.45M-$4.20-0.58

In the previous week, OS Therapies had 5 more articles in the media than RXi Pharmaceuticals. MarketBeat recorded 5 mentions for OS Therapies and 0 mentions for RXi Pharmaceuticals. RXi Pharmaceuticals' average media sentiment score of 0.00 beat OS Therapies' score of -0.19 indicating that RXi Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
OS Therapies Neutral
RXi Pharmaceuticals Neutral

OS Therapies presently has a consensus target price of $18.00, suggesting a potential upside of 997.56%. Given OS Therapies' stronger consensus rating and higher possible upside, equities research analysts plainly believe OS Therapies is more favorable than RXi Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
OS Therapies
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
2 Strong Buy rating(s)
3.40
RXi Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

OS Therapies beats RXi Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

Get RXi Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for RXII and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RXII and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

RXII vs. The Competition

MetricRXi PharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ Exchange
Market Cap$10.73M$797.98M$5.53B$9.41B
Dividend YieldN/A4.84%3.76%4.04%
P/E Ratio-0.581.4128.2619.78
Price / Sales1,073.1024.93413.4594.56
Price / CashN/A19.5635.8558.18
Price / Book3.187.058.115.65
Net Income-$12.45M-$3.55M$3.25B$257.97M

RXi Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RXII
RXi Pharmaceuticals
N/A$2.45
+0.8%
N/A-45.6%$10.73M$10K-0.58N/A
OSTX
OS Therapies
2.5165 of 5 stars
$1.58
-8.7%
$18.00
+1,039.2%
N/A$44.40MN/A-1.84N/A
EGRX
Eagle Pharmaceuticals
2.5522 of 5 stars
$3.25
+8.3%
N/A-37.0%$42.21M$257.55M0.00100Gap Down
ELYM
Eliem Therapeutics
N/A$1.28
+1.6%
N/A-79.3%$38.08MN/A-2.429
MRNS
Marinus Pharmaceuticals
2.1017 of 5 stars
$0.55
-0.2%
$3.92
+613.3%
-61.6%$30.32M$30.99M-0.22110
HILS
Hillstream BioPharma
N/A$1.69
-9.1%
N/A-55.5%$29.75MN/A-2.351Gap Up
ALLK
Allakos
3.4091 of 5 stars
$0.33
flat
$2.00
+507.7%
N/A$29.74MN/A-0.16190
CARA
Cara Therapeutics
0.2589 of 5 stars
N/AN/AN/A$24.33M$7.14M-0.2580News Coverage
Gap Down
High Trading Volume
NNVC
NanoViricides
0.4362 of 5 stars
$1.38
+0.3%
N/A-20.4%$22.24MN/A-1.9220
IBIO
iBio
1.4397 of 5 stars
$0.84
+6.7%
$4.30
+413.4%
-66.4%$13.84M$375K0.00100
ME
23andMe
N/A$0.50
-35.3%
N/A-94.4%$13.36M$208.78M-0.03770Gap Down
High Trading Volume

Related Companies and Tools


This page (NASDAQ:RXII) was last updated on 7/20/2025 by MarketBeat.com Staff
From Our Partners